BioWorld

Oct. 18, 2006

'Obvious' Buyout: Lilly Paying $2.1B For Cialis Partner ICOS

ICOS Corp., which through a successful joint venture with Eli Lilly and Co. commercialized the erectile dysfunction product Cialis, agreed to be acquired by Lilly in a deal valued at about $2.1 billion. (BioWorld Today) Read More

Roche, InterMune In HCV Deal With $530M Potential

Genzyme Paying $580M For AnorMED; Millennium Blinks

Memory's Phase IIa Study On Hold; Firm Raises $26M

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...